Summary of presentations from the 46th annual meeting of the American Society of Clinical Oncology (2010): Focus on supportive care issues related to lung cancer

Journal of Thoracic Oncology

Volumn 6, Issue 3, 2011, Pages 645-649

  Boehmer, Leigh ^a   Waqar, Saiama ^b   Butler, Sara ^a   Sezhiyan, Ananth ^b   Govindan, Ramaswamy ^b,c  

^a BARNES JEWISH HOSPITAL   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MO   (United States)

Author keywords

ASCO; Lung cancer; Supportive care; Update

Indexed keywords

ANTINEOPLASTIC AGENT; APREPITANT; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DALTEPARIN; DEXAMETHASONE; FENTANYL; FOSAPREPITANT; HYDROCORTISONE; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; METHYLPHENIDATE; NAPROXEN; NOSE SPRAY; OLANZAPINE; ONDANSETRON; OXALIPLATIN; PALONOSETRON; PECTIN; PLACEBO; PLATINUM; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; STATIN; TESTOSTERONE; TRYPTOPHAN; TUMOR NECROSIS FACTOR ALPHA; WARFARIN;

ALTERNATIVE MEDICINE; CANCER PAIN; CONFERENCE PAPER; FATIGUE; HUMAN; MEDICAL SOCIETY; NAUSEA AND VOMITING; PRIORITY JOURNAL; VENOUS THROMBOEMBOLISM;

EID: 79951771506     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318200f95d     Document Type: Conference Paper

References (37)

1. Peters L, Sellick K. Quality of life of cancer patients receiving inpatient and home-based palliative care. J Adv Nurs 2006;53:524-533. (Pubitemid 43443492)
2. Brazil K, Sussman J, Bainbridge D, et al. Who is responsible? The role of family physicians in the provision of supportive cancer care. J Oncol Pract 2010;6:19-24.
3. American Society of Clinical Oncology, Kris MG, Hesketh PJ, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 2006;24:2932-2947. (Pubitemid 46630595)
4. Hatoum HT, Lin S, Buchner D, et al. Chemotherapy-induced nausea and vomiting-associated hospital and ER visits in real-world practice: palonosetron versus other 5-HT3-RA anti-emetic regimens. J Clin Oncol 2010;7S:abstr 9127.
5. Gralla R, Rapoport BL, Jordan K, et al. Assessing the magnitude of antiemetic benefit with the addition of the NK1 receptor antagonist (NK1) aprepitant for all platinum agents: analysis of 1,872 patients in prospective randomized clinical phase III trials (RCTs). J Clin Oncol 2010;7S:abstr 9057.
6. Grunberg S, Chua DT, Maru A, et al. Phase III randomized double-blind study of single-dose fosaprepitant for prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 2010;7S:abstr 9021.
7. Navari RM, Gray SE, Kerr AC. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting (CINV): a randomized phase III trial. J Clin Oncol 2010;7S:abstr 9020.
8. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999;91:1616-1634. (Pubitemid 29479929)
9. Blackhall L, Petroni G, Shu J, et al. A pilot study evaluating the safety and efficacy of modafinal for cancer-related fatigue. J Palliat Med 2009;12:433-439.
10. National Cancer Institute. Fatigue PDQ Summary. Available at: . Accessed June 14, 2010.
11. Bharne AA, Mills P, Bardwell W, et al. Biochemical correlates of fatigue in patients at a comprehensive cancer center. J Clin Oncol 2010;28(7S):abstr 9162.
12. NCCN Clinical Practice Guidelines in Oncology. Cancer-Related Fatigue. V. 1.2010. Available at: PDF/fatigue.pdf. Accessed June 17, 2010.
13. Breitbart W, Alici Y. Pharmacologic treatment options for cancerrelated fatigue: current state of clinical research. Clin J Oncol Nurs 2008;12(Suppl 5):27-36.
14. Barton DL, Moraska AR, Sood A, et al. Long-acting methylphenidate for cancer-related fatigue: NCCTG trial N05C7. J Clin Oncol 2010; 28(7S):abstr 9004.
15. Yennurajalingam S, Palmer JL, Li Z, et al. Factors associated with response to methylphenidate in advanced cancer patients with cancerrelated fatigue. J Clin Oncol 2010;28(7S):abstr 9005.
16. Lesser GJ, Case LD, Stark N, et al. A randomized double-blind placebocontrolled study of oral coenzyme Q10 to relieve self-reported cancertreatment- related fatigue in newly diagnosed breast cancer patients. J Clin Oncol 2010;28(7S):abstr 9006.
17. Campos MP, Riechelmann R, Martins LC, et al. Effect of guaran (Paullinia cupana) on fatigue in breast cancer patients undergoing systemic chemotherapy. J Clin Oncol 2010;28(7S):abstr 9007.
18. Desandre PL, Quest TE. Management of cancer-related pain. Hematol Oncol Clin North Am 2010;24:643-658.
19. Hjermstad MJ, Fainsinger R, Kaasa S, et al. Assessment and classification of cancer pain. Curr Opin Support Palliat Care 2009;3:24-30.
20. De Marinis F, Eberhardt W, Harper PG, et al. Bisphosphonate use in patients with lung cancer and bone metastases: recommendations of a European expert panel. J Thorac Oncol 2009;4:1280-1288.
21. Kirshner JJ, Heckler CE, Dakhil SR, et al. Prevention of pegfilgrastiminduced bone pain (PIP): a URCC CCOP randomized, double-blind, placebocontrolled trial of 510 cancer patients. J Clin Oncol 2010;7S:abstr 9014.
22. Fallon MT, Davies A, Gatti A, et al. Efficacy and safety of fentanyl pectin nasal spray versus immediate-release morphine sulphate tablets in the treatment of breakthrough cancer pain. J Clin Oncol 2010;7S:abstr 9016.
23. Burton AW, Gabrail NY, Radbruch L, et al. Long-term safety, tolerability, and acceptability of fentanyl pectin nasal spray in the treatment of breakthrough cancer pain. J Clin Oncol 2010;7S:abstr 9094.
24. Le Maitre A, Ding K, Shepherd FA, et al. Anticoagulation and bleeding: a pooled analysis of lung cancer trials of the NCIC Clinical Trials Group. J Thorac Oncol 2009;4:586-594.
25. Dogan M, Demirkazik A. Venous thromboembolism in patients with cancer and its relationship to the coagulation cascade and vascular endothelial growth factor. Support Cancer Ther 2005;3:28-34.
26. Rocha AT, Paiva EF, Lichtenstein A, et al. Risk-assessment algorithm and recommendations for venous thromboembolism prophylaxis in medical patients. Vasc Health Risk Manag 2007;3:533-553. (Pubitemid 47553493)
27. Griffiths GO, Burns S, Noble SI, et al. FRAGMATIC: a randomized phase III clinical trial investigating the effect of fragmin added to standard therapy in patients with lung cancer. BMC Cancer 2009;9:355.
28. Connolly GC, Khorana AA. Emerging risk stratification approaches to cancer-associated thrombosis: risk factors, biomarkers and a risk score. Thromb Res 2010;125(suppl 2):S1-S7.
29. Nalluri SR, Chu D, Keresztes R, et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a metaanalysis. JAMA 2008;300:2277-2285.
30. Marcy P, Chamorey E, Figl A, et al. Venous thrombosis associated with central venous catheter in cancer patients with surgical chest port or venography-guided arm port insertion: a randomized controlled study. J Clin Oncol 2010;28(7S):abstr 9158.
31. Undas A, Brummel-Ziedins KE, Mann KG. Statins and blood coagulation. Arterioscler Thromb Vasc Biol 2005;25:287-294. (Pubitemid 40189147)
32. Glynn RJ, Danielson E, Fonseca FA, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 2009;360:1851-1861.
33. Giever TA, Adwan KM, Cheng Y, et al. Comparison of venous thromboemboli incidence in cancer patients who are on statin therapy versus those not on statin therapy. J Clin Oncol 2010;28(7S):abstr 9033.
34. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146-153. (Pubitemid 36818784)
35. Simons WR, Choe Y, Powers A, et al. A real-world evaluation of the effectiveness of dalteparin in the prevention of recurrent venous thromboembolism compared to warfarin in patients with cancer. J Clin Oncol 2010;28(7S):abstr 9115.
36. Tascilar M, de Jong FA, Verweij J, et al. Complementary and alternative medicine during cancer treatment: beyond innocence. Oncologist 2006; 11:732-741. (Pubitemid 44157561)
37. Micke O, Buntzel J, Kisters K, et al. Complementary and alternative medicine in lung cancer patients: a neglected phenomenon? Front Radiat Ther Oncol 2010;42:198-205.